Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study

Decuypere, Flore; Sermon, Jan; Geerts, Paul; Denee, Tom; Vos, Cedric De; Malfait, Bart; Lamotte, M; Mulder, Cornelis L.

doi:10.1371/journal.pone.0179049

Cited by 26 publications

(28 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The handprint considers the effect of antipsychotic treatment which keeps patients more stable, reducing the probability of an acute psychotic episode or relapse. This leads to a reduction in Human Health disability of the treated patients and is based on a Markov model that simulates treatment over one year [32,58,[62][63][64][65][66][67][68][69][70]. A new Markov model was developed to simulate disease outcomes of patients for PP1M and PP3M treatment, as well as Treatment Interruption.…”

Section: Goal and Scopementioning

confidence: 99%

Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals

et al. 2020

View full text Add to dashboard Cite

Life Cycle Assessment typically focuses on the footprint of products and services, expressed on three Areas of Protection (AoP): Human Health, Ecosystems and Resources. While the handprint is often expressed qualitatively, quantified handprints have recently been compared directly to the footprint concerning one AoP: Human Health. We propose to take this one step further by simultaneously comparing the quantified handprint and footprint on all AoPs through normalization and weighting of the results towards a single score. We discuss two example cases of a pharmaceutical treatment: mebendazole to treat soiltransmitted helminthiases and paliperidone palmitate to treat schizophrenia. Each time, treatment is compared to 'no treatment'. The footprint of health care is compared to the handprint of improved patient health. The handprint and footprint were normalized separately. To include sensitivity in the normalization step we applied four sets of external normalization factors for both handprint (Global Burden of Disease) and footprint (ReCiPe and PROSUITE). At the weighting step we applied 26 sets of panel weighting factors from three sources. We propose the Relative Sustainability Benefit Rate (RSBR) as a new metric to quantify the relative difference in combined handprint and footprint single score between two alternatives. When only considering the footprint, the first case study is associated with an increased single score burden of treatment compared to 'no treatment', while in the second case study treatment reduces the single score burden by 41.1% compared to 'no treatment'. Also including the handprint provided new insights for the first case study, now showing a decrease of 56.4% in single score burden for treatment compared to 'no treatment'. For the second case study the reduction of single score burden was confirmed as the handprint burden was also decreased because of treatment by 9.9%, reinforcing the findings.

show abstract

Section: Goal and Scopementioning

confidence: 99%

Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals

et al. 2020

View full text Add to dashboard Cite

show abstract

“…9 , 10 Mode of administration includes daily oral medication and long-acting injectable (LAI) medications, which may be prescribed once every 2 weeks, 1 month, or 3 months. 11 , 12 Current treatments have a high rate of discontinuation. 13 Reasons identified for treatment discontinuation include side effects, lack of cooperation from the patient, sudden subjective symptom improvement, forgetfulness, lack of awareness about the illness, and lack of support.…”

Section: Introductionmentioning

confidence: 99%

Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling

Bridges¹,

Beusterien²,

Heres³

et al. 2018

PPA

View full text Add to dashboard Cite

ObjectiveThis study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan.MethodsPeople aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best–worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment.ResultsAcross 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight =19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%; p=0.059) and preferred LAI (46% versus 32%; p=0.151).ConclusionsPeople with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement.

show abstract

“…Despite the backdrop, few studies attempted to describe how this novel paradigm affected prescribing practices. Available epidemiological data are limited to schizophrenia patients [ 39 – 43 ] and highly selected populations [ 40 , 44 , 45 ]. In order to fill the gap in the research literature, the cross-sectional phase of the STAR Network “Depot” Study aimed at evaluating how the claimed cultural change in LAIs prescription may have affected real-world practices, by (a) describing the main socio-demographic and clinical features (including symptom profiles, adherence and attitude towards treatments) of a large, representative, unselected population of patients starting a LAI medication, and (b) exploring possible predictors of the class of LAI prescribed.…”

Section: Introductionmentioning

confidence: 99%

Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy

et al. 2018

View full text Add to dashboard Cite

BackgroundFor many years, long-acting intramuscular (LAI) antipsychotics have been prescribed predominantly to chronic and severe patients, as a last resort when other treatments failed. Recently, a broader and earlier use of LAIs, particularly second-generation LAIs, has been emphasized. To date, few studies attempted to frame how this change in prescribing took place in real-world practice. Therefore, this study aimed to describe the clinical features of patients prescribed with LAIs, and to explore possible prescribing differences between first- and second-generations LAIs under ordinary clinical practice in Italy.MethodsThe STAR Network “Depot” Study is an observational, longitudinal, multicenter study involving 35 centers in Italy. In the cross-sectional phase, patients prescribed with LAIs were consecutively recruited and assessed over a period of 12 months. Descriptive statistics and multivariable logistic regression analyses were employed.ResultsOf the 451 recruited patients, 61% were males. The level of social and working functioning was heterogeneous, as was the severity of disease. Seventy-two per cent of the patients had a diagnosis of the schizophrenia spectrum. Seventy per cent were prescribed with second-generation antipsychotic (SGA) LAIs (mostly paliperidone, aripiprazole and risperidone). Compared to first-generation antipsychotic (FGA) LAIs, patients prescribed with SGA LAIs were more often younger; employed; with a diagnosis of the schizophrenia spectrum or bipolar disorder; with higher levels of affective symptoms; with fewer LAI prescriptions in the past.DiscussionLAIs’ prescribing practices appear to be more flexible as compared to the past, although this change is mostly restricted to SGA LAIs.

show abstract

Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study

Cited by 26 publications

References 54 publications

Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals

Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals

Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling

Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy

Contact Info

Product

Resources

About

Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study

Cited by 26 publications

References 54 publications

Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals

Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals

Quantifying the treatment goals of people recently diagnosed with schizophrenia using best&ndash;worst scaling

Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy

Contact Info

Product

Resources

About

Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling